Tag
The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resou
A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.
A randomized phase II trial of the bispecific HER2-directed ADC TQB2102 (n=104) showed robust total pathologic complete response rates (tpCR 57.7–76.9% across cohorts) with manageable grade ≥3 toxicity and no treatment‑related deaths, suppo
SunRISe-4 reports higher pCR, pOR, and 1‑year RFS for neoadjuvant TAR‑200 plus cetrelimab versus cetrelimab alone in cisplatin‑ineligible/refusing MIBC, with urinary and circulating tumor DNA MRD correlating with outcomes.
In a multicentre phase 2 single-arm trial, oral chidamide added to standard epirubicin–cyclophosphamide followed by docetaxel produced an RCB 0–I rate of 35.2% in stage II–III HR+/HER2– breast cancer, with high rates of grade 3–4 neutropeni
A phase 1 trial reports tolerable single‑fraction preoperative stereotactic partial‑breast irradiation (30–38 Gy) with low toxicity, preserved cosmesis, and high pathologic complete response rates when surgery was delayed beyond ~9 months o
Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients in
The PREOPANC-2 trial compared neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer, finding no significant overall survival difference between the two regimens.
Neoadjuvant osimertinib, alone or with chemotherapy, significantly improves major pathological response rates in resectable EGFR-mutated NSCLC, offering a promising approach to enhance surgical outcomes and event-free survival with an accep
The CHINOREC phase 2 trial demonstrates that adding ipilimumab and nivolumab to standard neoadjuvant chemoradiotherapy in rectal cancer is safe and feasible, showing promising clinical activity but no significant improvement in complete res
The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.
Adding sintilimab to short-course radiotherapy and chemotherapy significantly increased pathological complete response rates in locally advanced rectal cancer, with manageable safety.
